Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
Wilms' tumor gene 1 (WT1) gene expression was analyzed in 32 patient with acute myeloid leukemia (AML) and 18 with acute lymphoblastic leukemia (ALL) to investigate whether it could serve as a MRD marker. Ninety-four percent of patients with acute leukemia showed high WT1 expression at presentation. WT1 expression as a MRD marker was evaluated in 36 patients. The rise of WT1 expression preceded the hematological relapse by approximately 4 months (mean time 129 days; range 6-298). The prognostic significance of WT1 expression was analyzed in 30 patients with AML. WT1 expression higher than 20 WT1 copies /10(4)ABL copies after induction and consolidation chemotherapy was associated with shorter OS. WT1 expression analysis could be a useful tool for MRD monitoring in acute leukemia.
Nowakowska-Kopera
Alicja
A
Department of Hematology, Collegium Medicum, Jagiellonian University, Cracow, Poland. anowakowskakopera@gmail.com
Sacha
Tomasz
T
Florek
Izabela
I
Zawada
Magdalena
M
Czekalska
Sylwia
S
Skotnicki
Aleksander B
AB
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D003199:Computer Systems; D018572:Disease-Free Survival; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D016162:Genes, Wilms Tumor; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D018365:Neoplasm, Residual / Q000737:chemistry / Q000175:diagnosis; D016133:Polymerase Chain Reaction / Q000379:methods*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D025721:WT1 Proteins / Q000096:biosynthesis*; D055815:Young Adult
D009363:Neoplasm Proteins; D025721:WT1 Proteins